[At-211] PSMA-5

N/A

Report date: 2025/11/21 17:15:23

Base Information

Drug Name[At-211] PSMA-5

Drug Alias Name[At-211] PSMA-5

ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Astatine > 211AtRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsPositron-emission tomography enhancers

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesOsaka University

China Registration ClassN/A

Develop Information

Active CompaniesOsaka University

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A